Please login to the form below
Chugai
This page shows the latest Chugai news and features for those working in and with pharma, biotech and healthcare.
Roche’s Soliris rival Enspryng bags FDA approval
The new NMOSD treatment was originally designed by Roche’s Japanese subsidiary Chugai, using novel recycling antibody technology.
Latest news
-
Medimmune-born Viela files $150m IPO, eyes first product launch
Meanwhile, Japan’s Chugai also has positive phase 3 data with its NMOSD candidate satralizumab, an interleukin-6 inhibitor partnered with Roche.
-
Chugai gains FDA breakthrough status for rare CNS treatment
Adds to company's BTD roll-call. The FDA has granted Breakthrough Therapy Designation to Chugai’s satralizumab, a treatment currently in phase 3 for the rare CNS disorders neuromyelitis optica ... Satralizumab is a recycling antibody created via
-
The year of the blockbuster
Hemlibra (emicizumab) from Roche/Chugai:A novel approach to treating haemophilia A with inhibitors, once-weekly Hemlibra (emicizumab) is a bispecific antibody that simultaneously binds to both factor IXa and factor
-
Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat
s crenezumab and Roche/Chugai’s gantenerumab.
-
First blood to Roche in Hemlibra patent fight with Shire
A Tokyo court has found in favour of the Swiss group and recommended that Shire’s challenge against majority-owned Japanese affiliate Chugai should be dismissed. ... A ruling on the US patent battle could come later this year, according to Shire, which
More from news
Approximately 6 fully matching, plus 38 partially matching documents found.
Latest Intelligence
-
Insights from Cannes Lions Health Festival 2018
Case Study: Ouchie . Agency: Havas Lynx. Client: Chugai/Roche. Award: Silver Lion.
-
Japanese pharma pulls no punches with post-Brexit UK
The level of investment on the pharmaceutical side is considerable. The Japanese Pharmaceutical Group (JPG), an association of nine drugmakers - Astellas, Chugai, Daiichi-Sankyo, Eisai, Kowa, Mitsubishi Tanabe, Otsuka, Shionogi and
-
Deal Watch May 2016
In the ever popular oncology field, Chugai has signed up with Osaka University for a multiyear investment worth $91.1m to focus on the development of treatments for cancer and the
-
Medius Deal Watch table for March 2015
225. Athersys / Chugai. Licence and collaboration Japan. Phase 2 stem cell therapy for treatment of ischaemic stroke.
-
Pharma deals during August 2014
Rumours of a $10bn Chugai bid have swirled for weeks but to no avail. ... This is Roche's largest acquisition since 2009 when the remaining stake in Genentech was acquired and may well have put paid to plans to fully acquire Chugai.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
New hires at Crescendo, Healx and Galecto
late phase clinical trials. Before that, he was clinical research physician at Chugai Pharma Europe, where he led clinical development for a bispecific T-cell engaging antibody programme and other early
-
Former Roche CEO and chairman joins Arix Bioscience
He is currently chairman of Diageo, a consumer goods company, and a non-executive director of Chugai P harmaceuticals, Citigroup and Kite Pharma.
-
Dr Hamina Patel moves from J&J to Evgen Pharma
Dr Patel has spent more than 15 years in the industry, and in addition to J&J she has also worked at Celltech and Chugai.
-
Chugai appoints Ruth Currie as MD of its UK business
She replaces John Halls, who has been promoted. Chugai Pharmaceuticals has promoted Ruth Currie to managing director of its UK business. ... In her new role, Currie will oversee all UK commercial operations of Chugai, which has been a subsidiary of Roche
More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
Account Manager
-
Competitive salary with bonus and benefits
-
Head of Copy
-
£ competitive
- Graduate Business Analyst, Healthcare Communications – Pharma/ S...
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Editorial Team Leader, Medical Communications, Oxford
-
Competitive Salary
- Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
- AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients
- Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results
- GSK appoint Tony Wood as chief scientific officer
- Almirall and IRB Barcelona announce new research collaboration
- Home or away: where next for pharmaceutical symposia?
- ARISE - a strategic healthcare communication planning process from Bedrock
- Pfizer and BioNTech start clinical trial for Omicron-based COVID-19 vaccine
- FDA restricts use of certain antibody treatments for COVID-19
- Let's explore new frontiers
- FDA grants priority review for Roche’s Evrysdi for spinal muscular atrophy in babies
- Ipsen’s Sohonos approved by Health Canada
- Why pharma must get smart in its approach to customer engagement
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
- Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies
- Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy
- Amgen’s Lumykras receives conditional marketing authorisation from EC
- AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- Personalised medicine: driving a need for greater diversity in clinical trials
- Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
- Cervical Cancer Prevention Month
- In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
